A Moving Target: Low VWF versus Type 1 von Willebrand Disease

A Moving Target: Low VWF versus Type 1 von Willebrand Disease

How a level that drifts with age, pregnancy, and the definition itself makes a poor master, and how even desmopressin, the treatment, carries its own risk.

By William C. Aird, MD

Case Presentation

A woman in her early forties has carried a diagnosis of type 1 von Willebrand disease since she was thirteen, when uncontrollable nosebleeds led to a workup at an academic center, where a prolonged bleeding time and a von Willebrand panel established the label. Her mother and three maternal aunts carry the same diagnosis and have needed desmopressin for their procedures.

Her bleeding is real but modest. As a teenager, a surgery had to be aborted for bleeding when desmopressin was withheld. She bruised heavily as a child, enough that others wondered about her home. She still has a few nosebleeds a year, which she manages with pressure. Against that, she has quietly tolerated several procedures with desmopressin cover, including deliveries and an appendectomy, and, notably, her menstrual bleeding has always been light, not heavy. Now she faces sinus and nasal surgery, and the question of how to cover her returns.

By current diagnostic criteria, how are her von Willebrand factor levels best classified?

Explanation

Current criteria reserve a formal diagnosis of type 1 von Willebrand disease for levels under 30 IU/dL. Her values, in the high forties to the sixties, sit above that line, in or just above the band from 30 to 50 that is now labeled “low VWF.” That category behaves as a modifiable bleeding risk and frequently carries no demonstrable mutation in the VWF gene, which sets it apart from classic, monogenic type 1 disease. Two forces keep her number from holding still. Von Willebrand factor rises with age, so her levels at thirteen were likely lower and may well have met the older, higher cutoff then. And von Willebrand factor is an acute phase reactant that climbs steeply with estrogen and pregnancy, which is why a panel drawn in her third trimester read between 139 and 195. The label was applied in the era of the bleeding time and a 50 percent threshold. The biology and the definition have both moved since.

Her current levels do not meet the threshold for a diagnosis, yet she has a convincing personal and family bleeding history, including a surgery aborted for bleeding when desmopressin was withheld. What should anchor her perioperative management?

Explanation

A threshold is built for diagnosis, not for prophecy. Her phenotype is durable and predates every shift in the cutoff: the aborted surgery, the childhood bruising, the recurrent epistaxis, the striking family history. A documented bleed when desmopressin was withheld is worth more than any single level above or below a line. At the same time she is plainly not severe. Her factor VIII and her multimers are normal, and her bleeding is mild and occurs at compressible sites. The task is calibration, covering a real but modest risk without treating a soft diagnosis as though it were a dangerous one. Part of what makes her genuinely ambiguous rather than clear cut is that she lacks heavy menstrual bleeding, the most common manifestation of von Willebrand disease in women.

Reveal: what happened last time

For an earlier, more complex sinus operation, she received two doses of desmopressin twelve hours apart, along with intravenous maintenance fluids. Her sodium fell to 119, with symptoms, and she spent a brief stay in the intensive care unit before fully recovering. A single dose had never done this to her.

Desmopressin caused her hyponatremia by which mechanism?

Explanation

Desmopressin is a synthetic analog of vasopressin, engineered to keep the antidiuretic V2 activity while shedding the pressor V1 activity, which is exactly why it also releases stored von Willebrand factor and factor VIII from endothelium. But the antidiuretic effect is not free. The kidney holds on to water, and if the patient is also given hypotonic maintenance fluids and keeps drinking, the sodium is diluted. Two doses twelve hours apart, layered on maintenance fluids, is the classic recipe, and it drove her to 119 and into the unit. A single dose had never troubled her; the combination did. Severe acute hyponatremia can cause seizures, which is why this belongs in the foreground of any desmopressin plan, not in a footnote.

She now needs another procedure and strongly prefers desmopressin, because she remembers bleeding when it was withheld. Which plan best balances hemostasis against the risk of recurrent hyponatremia?

Explanation

Every element of the safe plan targets the mechanism. One dose rather than two limits the cumulative water retention. Withholding hypotonic and maintenance fluids and restricting oral intake removes the free water that does the diluting. A next-day sodium catches any trouble early. Option A supplies exactly the free water that caused the problem. Option D compounds the water load. Option C fails a specific rule: desmopressin and antifibrinolytics such as tranexamic acid are kept apart rather than combined, since stacking a stimulus that raises von Willebrand factor and factor VIII on top of a blockade of clot breakdown raises a theoretical thrombotic concern. The safest desmopressin is the least of it, given once, with the water carefully controlled.

Reveal: the road not taken

There was a real alternative on the table. Tranexamic acid, an antifibrinolytic, is especially effective at mucosal sites like the nose and mouth, where local fibrinolytic activity is high, and it carries no risk of hyponatremia at all. For a compressible nasal site in a mild bleeder, tranexamic acid alone would have been reasonable, and it was offered, with recombinant von Willebrand factor held in reserve for the rare emergency. She chose desmopressin anyway, because her own body had taught her what happens without it. The final plan honored that preference and then defended against its known hazard, rather than overriding her. In a disorder this mild and this personal, the workable answer was the one she could accept, made safe.

Teaching Points

• “Low VWF” is not simply mild type 1 disease under another name. Current criteria reserve a formal type 1 diagnosis for levels under 30 IU/dL, and the band from 30 to 50 is a distinct category that often carries no demonstrable VWF mutation and behaves as a modifiable risk rather than a monogenic disease.
• The von Willebrand factor level is a moving target. It rises with age, climbs steeply in pregnancy and with estrogen as an acute phase reactant, and runs lower in blood group O. A diagnosis anchored to one number inherits all of that drift, while the bleeding phenotype stays comparatively still and makes the steadier guide. This patient is blood group A, so the common group O explanation does not even account for her lower readings.
• Desmopressin’s antidiuresis is the price of its convenience. The same V2 activity that spares the blood pressure makes the kidney retain water, so repeated dosing with hypotonic fluids is the standard path to symptomatic hyponatremia. Dose limitation, isotonic fluids only as needed, fluid restriction, and a sodium check are the countermeasures.
• Keep desmopressin and antifibrinolytics apart. Sequencing them rather than combining them avoids stacking a procoagulant stimulus on top of fibrinolytic blockade.
• Tranexamic acid earns its place at mucosal sites. Where local fibrinolysis is high, as in the nose, mouth, and uterus, an antifibrinolytic is often sufficient on its own and sidesteps the water problem entirely.

Why This Case Matters

The other cases in this set show von Willebrand disease in full voice: a gain of function that clears platelets, a qualitative defect that cannot grip, an absence that disables everything at once. This one lives at the faint edge of the spectrum, where the label outruns the biology. Her number drifts with age, with pregnancy, and with the definition itself, while her bleeding history holds still, and the honest reading is that she has a genuine but modest tendency to bleed that no threshold was ever going to capture cleanly. Then the treatment for that modest tendency put her in an intensive care unit, which is the second lesson folded into the first: mildness is not safety, and the hazards of therapy have to be set against a bleeding risk that is itself uncertain. What resolves the case is not a better cutoff. It is judgment held steady between two errors, treating her as neither sicker nor safer than she is.